{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:24:14Z","timestamp":1777875854832,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>To estimate the incident risk of surgical intervention for nasolacrimal duct obstruction after radioactive iodine (RAI) treatment and elucidate the high-risk group of patients with thyroid cancer (TC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This is a nationwide, population-based cohort study using data from the Korean National Health Claims database. Among the entire South Korean population aged between 20 and 80 years from 2007 to 2019, all patients with TC were included. Among all TC patients, a cohort was established by classifying it into the RAI and non-RAI groups according to whether RAI treatment was performed during the recruitment period. A log-rank analysis was used to evaluate the risk of nasolacrimal duct obstruction surgery in the RAI group compared with that in the non-RAI group. The Cox proportional hazards regression analysis was performed to calculate the adjusted hazard ratio (HR). The analysis was performed stratified by the age group, sex, frequency of RAI treatment, and cumulative dose of\n                      <jats:sup>131<\/jats:sup>\n                      I.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 55,371 TC patients, who received RAI treatment, 515 (0.93%) underwent nasolacrimal duct obstruction surgeries, and among 56,950 TC patients, who did not receive RAI treatment, 72 (0.13%) underwent the surgeries. The average timing of incident nasolacrimal duct obstruction surgery was 3.8\u2009\u00b1\u20092.1 years after the first exposure to RAI. The incidence rate of nasolacrimal duct obstruction surgery was 104.04\/100,000 person-years in the RAI group. There was a significantly higher risk of nasolacrimal duct obstruction surgery (HR 7.50 [confidence interval, CI: 5.86\u20139.60],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the RAI group than in the non-RAI group. The risks significantly increased in the high-dose group (HR 14.15 [CI: 10.88\u201318.39]) and those younger than 50 years (HR 15.54 [CI: 9.76\u201324.72]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We quantified the risk of RAI-induced nasolacrimal duct obstruction surgery through a long-term follow-up of 9 years, which may contribute to estimating the general health care burden related to RAI treatment for TC patients in a practical setting. Great attention should be paid to its risk in patients younger than 50 years, especially in those treated with high doses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2021.0418","type":"journal-article","created":{"date-parts":[[2021,12,12]],"date-time":"2021-12-12T07:39:57Z","timestamp":1639294797000},"page":"544-551","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study"],"prefix":"10.1177","volume":"32","author":[{"given":"Ju-Yeun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Myongji Hospital, Hanyang University College of Medicine, Goyang, South Korea."},{"name":"Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea."},{"name":"Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung In","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0186"},{"key":"e_1_3_6_3_2","first-page":"120","article-title":"Iodine-131 for therapy of thyroid diseases. Physical and biological basis","volume":"15","author":"Wyszomirska A","year":"2012","unstructured":"Wyszomirska A. 2012. Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur, 15:120\u2013123.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"e_1_3_6_4_2","first-page":"299","article-title":"Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid","volume":"40","author":"Seidlin SM","year":"1990","unstructured":"Seidlin SM, , Marinelli LD, , Oshry E. 1990. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. CA Cancer J Clin, 40:299\u2013317.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0194599813479777"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e318124fdb6"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.iop.0000179369.75569.a8"},{"key":"e_1_3_6_8_2","first-page":"2479","article-title":"Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases","volume":"8","author":"Al-Qahtani KH","year":"2014","unstructured":"Al-Qahtani KH, , Al Asiri M, , Tunio MA, et al. 2014. Nasolacrimal duct obstruction following radioactive iodine 131 therapy in differentiated thyroid cancers: review of 19 cases. Clin Ophthalmol, 8:2479\u20132484.","journal-title":"Clin Ophthalmol"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000117340.41849.81"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.rlu.0000170013.84378.2a"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.IOP.0000092802.75899.F8"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000066"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10270-2"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.032"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000603"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e3283570fb8"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-020210"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0657"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910315)67:6<1539::AID-CNCR2820670613>3.0.CO;2-Q"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2006.00822.x"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000717"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0162"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108586"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv314"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00089"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0136"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2021.0418","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2021.0418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:08:41Z","timestamp":1777586921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2021.0418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1089\/thy.2021.0418"],"URL":"https:\/\/doi.org\/10.1089\/thy.2021.0418","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}